A multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of Irritable Bowel Syndrome (IBS)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2025 According to EnteroBiotix media release, company is continuing engagement with regulatory authorities to agree the next steps in its clinical development programme for EBX-102-02 in IBS. Based on these promising results, the company plans to proceed with a larger Phase 2b trial to confirm efficacy.
18 Mar 2025 According to EnteroBiotix media release, Mr Paul Goldsmith MD, FRCS, Consultant General Surgeon at the University of Manchester NHS Trust and Chief Investigator of the TrIuMPH study. and The Company expects to announce final data, inclusive of the IBS-D cohort, in Q3 2025.
18 Mar 2025 Initial results from the IBS-C cohort presented in the EnteroBiotix media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com